Title of Invention: Methods of evaluating immunogenicity of an agent using an artificial tissue construct Abstract: Artificial tissue constructs (TCs), methods of making the TCs, uses thereof, and kits comprising the TCs are provided. TCs are useful for vaccine evaluation for human adult, human non-newborn, and newborns. Detailed Description: Part general_description_paragraphs: Part CROSS REFERENCE TO RELATED APPLICATIONS: This application is a 35 U.S.C. § 371 National Phase Entry Application of International Application No. PCT/US2013/029517 filed Mar. 7, 2013, which designates the U.S., and which claims benefit under 35 U.S.C. § 119(e) of U.S. Provisional Application No. 61/607,796 filed on Mar. 7, 2012 and U.S. Provisional Application No. 61/617,874 filed Mar. 30, 2012, the contents of each of which are incorporated herein by reference in their entireties. Part FIELD OF INVENTION: Embodiments disclosed herein relate to the evaluation of immunomodulators, microbes, microbial components, adjuvants, and vaccines. Specifically, embodiments disclosed herein relate to methods, artificial tissue constructs apparatus and kits for vaccine evaluation for human adults, human newborns and human non-newborns. Part BACKGROUND OF THE INVENTION: Over the past decade, efforts have indicated the ability to culture mononuclear cells (MCs) in three-dimensional systems. Indeed, these principles have been incorporated in the development of platforms for the evaluation of adult vaccine responses. However, thus far, published tissue engineering work has not taken into account age-dependent changes in immunity in an organism, some of which depend on differences in soluble components of human autologous plasma. The immune responses of newborns and infants are distinct and not predictable from those of adults due to differences in both their cellular and humoral (i.e., soluble) components. Neonatal leukocytes and in particular monocytes and dendritic cells, demonstrate impairments in migration, Th1-polarizing cytokine production, and antigen-presenting cell (APC)-lymphocyte interactions. Of note, the known tissue engineering systems have employed xenologous materials such as fetal bovine serum, or have employed heat-treated pooled human serum and have therefore not taken into account immunomodulatory components unique to intact autologous neonatal plasma. Part SUMMARY: Embodiments disclosed herein relate to tissue constructs, methods of making and using such tissue constructs (TCs), and kits for vaccine evaluation for human adult, human non-newborn and newborns. It is the goal of the embodiments disclosed herein to provide human tissue constructs that are comprised largely or entirely of human materials with little or no xenologous, (non-human) materials, and are therefore, suitable for vaccine formulation evaluation for humans, and also for the evaluation of candidate immunomodulators, and adjuvants for humans. Another goal is to provide human tissue constructs suitable for testing vaccines that are to be used in vaccinating newborns. The human tissue constructs described herein are suitable for testing of agents, including but are not limited to immunomodulators, adjuvants, and vaccine formulations. The human tissue constructs allow a person to assess the safety and efficacy of new immune-response stimulating agents in a pre-clinical in vitro setting. In one embodiment, the purpose of testing serves to assess vaccine formulation safety, vaccine reactogenicity, and/or vaccine toxicity of a new formulation. In one embodiment, the assessment is achieved by generating data with the human tissue constructs disclosed and the new vaccine formulations, and comparing these data with those obtained in similar human tissue constructs for licensed and approved vaccines, i.e., by benchmarking to the known licensed and approved vaccines. The human tissue construct described herein is suitable because the constituents therein more closely resemble and recapitulate the immune cells and immune system of a newborn and a human. Such a human tissue construct is comprised essentially of human materials from newborns and/or a human, non-limiting example include primary leukocytes derived from human cord blood, intact human newborn plasma and human newborn platelet-poor plasma. In addition, the plasma, e.g., platelet-poor plasma is not depleted of components of cell signaling and immune responses, e.g., including, divalent cations, soluble complement, maternal antibodies, and plasma purine-metabolizing enzymes that generate immunomodulatory adenosine, etc. As used herein, in one embodiment, the term “intact” in the context of plasma or heparinized plasma/blood means that the plasma has not been heat treated. In another embodiment, the term “intact” in the context of plasma or heparinized plasma/blood means that the plasma has not depleted of any plasma components. In some embodiments, the term “intact” and “untouched” are used interchangeably. As used herein, the term “untouched heparin plasma” where the untouched refers to the plasma means that the plasma has not been heat treated or depleted in any way. In one embodiment, provided herein is a tissue construct (TC) comprising a cushion of extracellular matrix, a monolayer of human endothelial cells on the top of the matrix cushion (i.e., the cushion of extracellular matrix), and human mononuclear cells (MCs) that have extravasated through the monolayer of human endothelial cells (ECs) and are embedded within and colonized the cushion of extracellular matrix, and have differentiated to migratory dendritic cells. In one embodiment, provided herein is a method of making such a tissue construct (TC), the method comprising providing a cushion of extracellular matrix, culturing human endothelial cells (ECs) on the cushion of extracellular matrix in the presence of human plasma for a period of time sufficient for the cells to form a monolayer, adding human mononuclear cells (MCs) to the monolayer of human ECs, and culturing the human MCs in the presence of human serum albumin for a period of time sufficient for autonomous extravasation of the MCs through the monolayer of human endothelial cells, thereby facilitating MC colonization of the cushion of extracellular matrix beneath the monolayer of human endothelial cells, and allowing the autonomous differentiation of MCs into migratory dendritic cells. As used herein, “differentiation of MCs into migratory dendritic cells” means the same as “develop and transform to migratory dendritic cells”, and are used interchangeably. In one embodiment, provided herein is a method of preparing a population of human dendritic cells in vitro, the method comprising introducing an adjuvant/antigen/vaccine/immune-response stimulating agent in the presence of human plasma to a tissue construct (TC) described herein, incubating the TC with the adjuvant/antigen/vaccine formulation/immune-response stimulating agent in the presence of human plasma for a period of time sufficient to allow autonomous generation of differentiated human migratory dendritic cells that have escaped from the matrix cushion and reverse-transmigrated back across the monolayer of human endothelial cells, and collecting the reverse-transmigrated dendritic cells which have developed into immature and mature antigen-presenting cells in the presence of the adjuvant/antigen/vaccine formulation/immune-response stimulating agent. In another embodiment, provided herein is a method of preparing a population of human dendritic cells in vitro, the method comprising first preparing or providing a tissue construct (TC) comprising extravasated human mononuclear cells (MCs) in a cushion of extracellular matrix with an overlying endothelial monolayer, the human MCs having differentiated therein into migratory dendritic cells, then introducing an adjuvant/antigen/vaccine formulation/immune-response stimulating agent in the presence of human plasma to the tissue construct, incubating the TC with the adjuvant/antigen/vaccine/immune-response stimulating agent in the presence of human plasma for a period of time sufficient to allow reverse-transmigration of the differentiated human migratory dendritic cells from the cushion of extracellular matrix and monolayer of endothelial cells, and collecting the reverse-transmigrated dendritic cells which have developed into immature and mature antigen-presenting cells in the presence of the adjuvant/antigen/vaccine formulation/immune-response stimulating agent. In another embodiment, provide herein is a method of preparing a population of dendritic cells in vitro, the method comprising: (a) culturing human endothelial cells (ECs) on a cushion of extracellular matrix in the presence of human plasma for a period of time sufficient to obtain a monolayer; (b) introducing human mononuclear cells (MCs) to the monolayer of human ECs; (c) culturing the human MCs in the presence of human serum albumin for a period of time sufficient to allow the human MCs to autonomous extravasate of the monolayer of endothelial cells, colonize the cushion of extracellular matrix and eventually differentiate into migratory dendritic cells; (d) removing non-extravasated MCs after the period of time in step c; (e) introducing to the culture of step d with an adjuvant/antigen/vaccine formulation/immune-response stimulating agent in the presence of human plasma; (f) incubating the culture of step (e) for a period of time sufficient to allow reverse-transmigration of the differentiate migratory dendritic cells from the cushion of extracellular matrix and monolayer of ECs; and (g) collecting the reverse-transmigrated dendritic cells which have developed into immature and mature antigen-presenting cells in the presence of the adjuvant/antigen/vaccine formulation/immune-response stimulating agent. In one embodiment, provided herein is an in vitro method for evaluating the effectiveness of a vaccine in eliciting an immune response to the vaccine, the method comprising: co-culturing human CD4+ CD45RA+ naïve T cells with a first population of human dendritic cells in the presence of human plasma, wherein the human dendritic cells are antigen-presenting cells developed in the presence of the vaccine formulation being tested and in the presence of human plasma; incubating the co-culture of human dendritic cells and human CD4+ CD45RA+ naïve T cells in the presence of human plasma for a period of time sufficient to cause primary activation and proliferation of the CD4+ CD45RA+ naïve T cells to become CD4+ CD45RO+ T cells; introducing the resultant activated human CD4+ CD45RO+ T cells in culture to a second population of human dendritic cells in the presence of human plasma, wherein the human dendritic cells are antigen-presenting cells developed in the presence of the vaccine formulation being tested and in the presence of human plasma; co-culturing the second population of human dendritic cells and the activated human CD4+ CD45RO+ T cells for a period of time sufficient to cause further activation and proliferation of the CD4+ CD45RO+ T cells in culture; and analyzing for the production of cytokines wherein the presence of cytokines over that in the absence of added dendritic cells indicates that the vaccine formulation being tested is an effective vaccine in stimulating a human immune response. In one embodiment, the production of prostaglandin E2 (PGE2) over that in the absence of added dendritic cells indicates that the vaccine formulation being tested is an effective vaccine in stimulating a human immune response. Very high PGE2 production induced by a novel vaccine formulation relative to licensed vaccines may also indicate potential for reactogenicity of a vaccine (eg, local reaction or fever). In one embodiment, provided herein is an in vitro method for evaluating the effectiveness of an adjuvant/antigen/vaccine formulation/immune-response stimulating agent in eliciting an immune response to an antigen/vaccine formulation/immune-response stimulating agent, the method comprising: co-culturing human CD4+ CD45RA+ naïve T cells with a first population of human dendritic cells in the presence of human plasma, wherein the human dendritic cells are antigen-presenting cells developed in the presence of the adjuvant/antigen/vaccine formulation/immune-response stimulating agent being tested and in the presence of human plasma; incubating the co-culture of human dendritic cells and human CD4+ CD45RA+ naïve T cells in the presence of human plasma for a period of time sufficient to cause primary activation and proliferation of the CD4+ CD45RA+ naïve T cells to become CD4+ CD45RO+ T cells; introducing the resultant activated human CD4+ CD45RO+ T cells in culture to a second population of human dendritic cells in the presence of human plasma, wherein the human dendritic cells are antigen-presenting cells developed in the presence of the an adjuvant/antigen/vaccine formulation/immune-response stimulating agent being tested and in the presence of human plasma; co-culturing the second population of human dendritic cells and the activated human CD4+ CD45RO+ T cells for a period of time sufficient to cause further activation and proliferation of the CD4+ CD45RO+ T cells in culture; and analyzing for the production of cytokines wherein the presence of cytokines over that in the absence of added dendritic cells indicates that the adjuvant/antigen/vaccine formulation/immune-response stimulating agent being tested is an effective vaccine in stimulating or promoting the stimulation (e.g. in the case of an adjuvant) of a human immune response. In one embodiment, the production of PGE2 over that in the absence of added dendritic cells indicates that the vaccine formulation being tested is an effective vaccine in stimulating a human immune response. In one embodiment, provided herein is an in vitro method for evaluating the effectiveness of an adjuvant/antigen/vaccine formulation/immune-response stimulating agent in eliciting an immune response to an antigen/vaccine formulation/immune-response stimulating agent, the method comprising: providing a first and second population of human dendritic cells, wherein the human dendritic cells are antigen-presenting cells developed in the presence of the adjuvant/antigen/vaccine formulation/immune-response stimulating agent being tested and in the presence of human plasma; co-culturing human CD4+ CD45RA+ naïve T cells with the first population of human dendritic cells in the presence of human plasma; incubating the co-culture of human dendritic cells and human CD4+ CD45RA+ naïve T cells in the presence of human plasma for a period of time sufficient to cause activation and proliferation of the CD4+ CD45RA+ naïve T cells to become CD4+ CD45RO+ T cells; introducing to the resultant activated human CD4+ CD45RO+ T cells in culture to the second population of human dendritic cells in the presence of human plasma; co-culturing the second population of human dendritic cells and the activated human CD4+ CD45RO+ T cells for a period of time sufficient to cause further activation and proliferation of the CD4+ CD45RO+ T cells in culture; and analyzing for the production of cytokines wherein the presence of cytokines over that in the absence of added dendritic cells indicates that the adjuvant/antigen/vaccine formulation/immune-response stimulating agent is an effective adjuvant/antigen/vaccine formulation/immune-response stimulating agent respectively in stimulating or promoting (e.g., an adjuvant) the stimulation of a human immune response. In one embodiment, the production of PGE2 over that in the absence of added dendritic cells indicates that the vaccine formulation being tested is an effective vaccine in stimulating a human immune response. In one embodiment, the human plasma is human PPP. In one embodiment, the first and second population of human dendritic cells, and the human CD4+ CD45RA+ naïve T cells are autologous, that is the cells are all derived from one individual human. In another embodiment, the pattern of cytokines produced, e.g., Th1, Th2, Th17 can also be analyzing and compared to those cytokine patterns produced in the absence of added dendritic cells and in comparison to licensed vaccines. Comparison with licensed vaccines is known as benchmarking. In one embodiment, provided herein is an in vitro method for evaluating the effectiveness of an adjuvant/antigen/vaccine formulation/immune-response stimulating agent in eliciting an immune response to the adjuvant/antigen/vaccine formulation/immune-response stimulating agent, the method comprising: introducing an adjuvant/antigen/vaccine formulation/immune-response stimulating agent to a tissue construct in the presence of human plasma, wherein the tissue construct was previously prepared by: providing a cushion of extracellular matrix comprising human extracellular matrix material such as collagen and/or fibronection, incubating the extracellular matrix cushion in the presence of glucose-6-phosphate for a sufficient period of time to allow collagen maturation, seeding the cushion of extracellular matrix with human ECs, culturing the human ECs to a confluent monolayer in the presence of human plasma, introducing human MCs to the confluent monolayer of human ECs in the presence of non-heat inactivated human serum albumin, incubating for a period of time sufficient to allow the MCs to undergo autonomous extravasation of the confluent monolayer of human endothelial cells wherein the extravasated human MCs having differentiated to migratory dendritic cells, and removing the non-extravasated human MCs; incubating the tissue construct for a period of time sufficient for the differentiated migratory dendritic cells to reverse-transmigrated the confluent monolayer of human ECs, the differentiated migratory dendritic cells having developed to antigen-presenting dendritic cells in the presence of the adjuvant/antigen/vaccine formulation/immune-response stimulating agent added; collecting the reverse-transmigrated dendritic cells; co-culturing the antigen-presenting dendritic cells with human CD4+ CD45RA+ naïve T cells in the presence of human plasma; incubating the co-culture of dendritic cells and naïve T cells in the presence of human plasma for a period of time sufficient to cause activation and proliferation of the CD4+ CD45RA+ naïve T cells to become CD4+ CD45RO+ T cells; introducing the resultant activated human CD4+ CD45RO+ T cells to a second population of human dendritic cells in the presence of human plasma; co-culturing the dendritic cells and activated human CD4+ CD45RO+ T cells in the presence of human plasma for a period of time sufficient to cause further activation and proliferation of the human CD4+ CD45RA+ activated T cells in culture; and analyzing for the production of cytokines wherein the presence of cytokines over that in the absence of added dendritic cells indicates that the adjuvant/antigen/vaccine formulation/immune-response stimulating agent is an effective adjuvant/antigen/vaccine formulation/immune-response stimulating agent respectively in stimulating or promoting the stimulation of a human immune response. In one embodiment, the production of PGE2 over that in the absence of added dendritic cells indicates that the vaccine formulation being tested is an effective vaccine in stimulating a human immune response. In one embodiment, the human plasma is human PPP. In one embodiment, the first and second population of human dendritic cells, and the human CD4+ CD45RA+ naïve T cells are autologous, that is the cells are all derived from one individual human. In one embodiment, the human plasma is from a human newborn. In one embodiment, the first and second population of human dendritic cells, and the human CD4+ CD45RA+ naïve T cells are autologous and derived from a human newborn. In other embodiments, measurement of other biomarkers such as secreted cytokines, intracellular cytokines, surface cell markers and lymphocyte proliferation are performed to assess elicitation of an immune response. In one embodiment, the production of PGE2 over that in the absence of added dendritic cells indicates that the vaccine formulation being tested is an effective vaccine in stimulating a human immune response. Comparison of the measurement of these biomarkers against proper negative and positive controls (i.e., “benchmarking”) such as unstimulated condition, stimulation with an unrelated antigen and/or licensed vaccines can, indicate whether the candidate novel adjuvant/antigen/vaccine formulation/immune-response stimulating agent is likely safe and an effective vaccine in stimulating primary and/or secondary/recall human immune responses in a human, e.g., a human newborn. In one embodiment of any methods described, the first and second populations of human dendritic cells are developed in the presence of the same adjuvant/antigen/vaccine formulation/immune-response stimulating agent that is being evaluated. In one embodiment, the first and second populations of human dendritic cells are developed in the same TC; that is the antigen-presenting cells are developed at the same time and same procedure. For example, the collected antigen-presenting cells are divided into two batches, one batch is the first population of human dendritic cells that is incubated with CD4+ CD45RA+ naïve T cells. The remaining batch is the second population of human dendritic cells that is incubated with CD4+ CD45RO+ T cells. In one embodiment of any of the methods or TC described, the human plasma is human platelet-poor plasma. The measurement of the production of cytokines secreted is used to assess whether an immune response, e.g., an adaptive immune response have been elicited in the presence of the antigen-presenting dendritic cells. In other embodiments, analyses of other parameters are done to assess whether there is an elicitation of an immune response in the presence of the antigen-presenting dendritic cells. Non-limiting examples of parameters that can be studied include intracellular cytokines, PGE2, surface cell markers and cell proliferation. These measurements can be compared against appropriate negative and positive controls, such as unstimulated condition (e.g., in the absence of an antigen-presenting dendritic cells) and stimulation with an unrelated antigen, in order to determine whether the adjuvant/antigen/vaccine formulation/immune-response stimulating agent is an effective adjuvant/antigen/vaccine formulation/immune-response stimulating agent in stimulating primary and/or secondary/recall human immune responses respectively. Such responses can be “benchmarked” by comparison to licensed and government approved immunomodulators, pediatric and adult vaccine formulations. In one embodiment, the first and second population of human dendritic cells, and the human CD4+ CD45RA+ naïve T cells are autologous, that is the cells are all derived from one individual human. In one embodiment, provided herein is a kit for making a human tissue construct described herein. In another embodiment, provided herein is a kit for preparing a population of dendritic cells in vitro. In another embodiment, provided herein is a kit for evaluation the efficacy of an adjuvant/antigen/vaccine/immune response stimulating agent. The kit comprises the components necessary to prepare a human tissue construct, the components include but are not limited to at least a container for holding or containing the tissue construct, e.g., tissue culture vessel, at least one type of extracellular matrix, human endothelial cells, and glucose-6-phosphate. Accordingly, provided herein is a kit comprising at least a container for holding or containing a human tissue construct; at least one extracellular matrix; and glucose-6-phosphate. The kit can comprise also human endothelial cells. Alternatively, the kit provides at least one tissue construct. In one embodiment, the kit is used for age-specific evaluation of the efficacy of an adjuvant/antigen/vaccine/immune response stimulating agent. As used herein, “age-specific evaluation of efficacy” means evaluating the efficacy of an adjuvant/antigen/vaccine/immune response stimulating agent in eliciting an immune response in a human of a specific age or age group e.g., a newborn, an adolescent, a child, an adult or an adult is between 22-30, 31-40, 41-50 etc. In one embodiment of any of the methods or TCs described, the cushion of extracellular matrix comprising collagen. In another embodiment of any of the methods or TCs described, the cushion of extracellular matrix comprises at least collagen. In other embodiments of any of the methods or TCs described, the collagen is human collagen, bovine collagen or porcine collagen. In other embodiments of any of the methods or TCs described, the collagen is Type 1 collagen. In one embodiment of any of the methods or TCs described, the human collagen is human Type 1 collagen. In one embodiment of any of the methods or TCs described, the collagen is glycosylated or glycated. In one embodiment of any of the methods or TCs described, the collagen is glycosylated or glycated in the presence of glucose-6-phosphate. As used herein, glycation (sometimes called non-enzymatic glycosylation) is the result of, typically covalent, bonding of a protein or lipid molecule with a sugar molecule, such as fructose or glucose, without the controlling action of an enzyme. Glycated collagen has added sugars that are not the result of enzymatically catalyzed reaction. As used herein, glycosylation is the enzyme-controlled addition of sugars to protein or lipid molecules. Glycosylated collagen has added sugars that are added by enzymatically catalyzed reaction. Glycosylation or glycation of collagen rendering the collagen amenable to culturing endothelial cells on top of it. In one embodiment of any of the methods or TCs described, the added sugars on the glycosylated or glycated collagen provide adhesion sites of attachment of the endothelial cells. In one embodiment of any of the methods or TCs described, the human collagen used is matured human collagen. As used herein, the term “mature collagen” is defined as glycosylated or glycated collagen in the presence of glucose-6-phosphate. In one embodiment of any of the methods or TCs described, the human collagen is matured in the presence of glucose-6-phosphate for at least 48 h. In another embodiment of any of the methods or TCs described, the human collagen is human collagen matured in the presence of glucose-6-phosphate for up to 5 days. In another embodiment of any of the methods or TCs described, the human collagen is human collagen matured in the presence of glucose-6-phosphate for a period of about 2 to about 5 days. In one embodiment of any of the methods or TCs described, the cushion of extracellular matrix further comprises fibronectin. In one embodiment of any of the methods or TCs described, the fibronectin is human fibronectin. In one embodiment of any of the methods or TCs described, the cushion of extracellular matrix comprises at least a mixture of collagen and fibronectin. In another embodiment of any of the methods or TCs described, the cushion of extracellular matrix comprises at least a mixture of human collagen and human fibronectin. In one embodiment of any of the methods or TCs described, the ECs are human ECs. In one embodiment, the ECs are human primary ECs. In one embodiment of any of the methods or TCs described, the human ECs are cultured and grown in intact human plasma that is the plasma has not been fractionated into platelet rich and platelet poor fractions. Non-limiting, other exemplary of intact human plasmas are intact human newborn plasma and intact human adult plasma. In one embodiment of any of the methods or TCs described, the human primary ECs are cultured in the presence of intact human newborn plasma. In one embodiment of any of the methods or TCs described, the human newborn plasma is pooled human newborn plasma from plasma collected from more than one newborn. In one embodiment of any of the methods or TCs described, the human primary ECs are obtained from one single donor. In one embodiment of any of the methods or TCs described, where the human primary ECs are used, the human primary ECs are obtained from human umbilical cord, placenta, or human cadaver tissues. In one embodiment of any of the methods or TCs described, the human primary endothelial cells are cultured to a confluent monolayer. In one embodiment, the confluent monolayer is at least 90% confluent. In other embodiment, the confluent monolayer is about 90% to about 100% confluent. In other embodiment, the confluent monolayer is about 95% to about 100% confluent. In another embodiment, the confluent monolayer is about 100% confluent. In one embodiment of any of the methods or TCs described, the period of time to obtain a monolayer is at least 24 h. In other embodiment, the period of time to obtain a monolayer is about 24 h to about five days. In one embodiment of any of the methods or TCs described, the human plasma, human platelet poor plasma or human serum albumin is obtained or derived from a newborn or a non-newborn, wherein a non-newborn is an adult, an adolescent or a child. In one embodiment of any of the methods or TCs described, the human plasma is human newborn plasma. In one embodiment of any of the methods or TCs described, the human plasma, human platelet poor plasma or human serum albumin is not heat-inactivated. In another embodiment of any of the methods or TCs described, the human plasma, human platelet poor plasma or human serum albumin is heat inactivated. In one embodiment of any of the methods or TCs described, the human plasma is autologous intact plasma to the human MCs, dendritic cells and/or the CD4+ CD45RA+ naïve T cells used in the methods and tissue constructs described herein. In another embodiment of any of the methods or TCs described, the human plasma is non-heat inactivated human plasma. In another embodiment of any of the methods or TCs described, the human plasma is human platelet poor plasma. In one embodiment of any of the methods or TCs described, the human plasma is used at at least 40%. In one embodiment of any of the methods or TCs described, the human plasma is used at about 40% to about 100%. In one embodiment, the human plasma is used at about 50%. In one embodiment of any of the methods or TCs described, the human platelet poor plasma is used at a concentration of at least 50%. In one embodiment of any of the methods or TCs described, the human platelet poor plasma is used at about 50% to about 100%. In one embodiment of any of the methods or TCs described, the human platelet poor plasma is used at about 100%. In one embodiment of any of the methods or TCs described, the human serum albumin is used at least 0.05%. In one embodiment of any of the methods or TCs described, the human platelet poor plasma is used at about 0.05% to about 10%. In one embodiment of any of the methods or TCs described, the human platelet poor plasma is used at about 0.1%. In one embodiment of any of the methods or TCs described, the human plasma, human platelet poor plasma or human serum albumin does not contain a chelating agent. In one embodiment of any of the methods or TCs described, the human plasma, human platelet poor plasma or human serum albumin is prepared with heparin. In one embodiment of any of the methods or TCs described, the human plasma, human platelet poor plasma or human serum albumin is prepared in the absence of a chelating agent. In one embodiment of any of the methods or TCs described, the chelated ions are magnesium or calcium. In one embodiment of any of the methods or TCs described, the human plasma, human platelet poor plasma or human serum albumin is pooled from more than one donor, e.g., a newborn. In another embodiment, the human plasma, human platelet poor plasma or human serum albumin is from one donor. In one embodiment of any of the methods or TCs described, the human plasma, human platelet poor plasma or human serum albumin is obtained from human umbilical cord blood, placental blood or circulating peripheral blood. In one embodiment of any of the methods or TCs described, the human serum albumin is not heat inactivated or not heat treated. In one embodiment of any of the methods or TCs described, the human serum albumin is pyrogen-free. In one embodiment of any of the methods or TCs described, the human serum albumin is a clinical grade human serum albumin. In one embodiment of any of the methods or TCs described, the human plasma, human serum albumin, human platelet poor plasma, human ECs, human MCs, and human CD33+ and/or CD14+ selected monocytes used has been previously been cryopreserved. In one embodiment of any of the methods or TCs described, the human MCs or human CD33+ and/or CD14+ selected monocytes are derived from a newborn or a non-newborn, wherein a non-newborn is an adult, an adolescent or a child. In one embodiment of any of the methods or TCs described, the human MCs or human CD33+ and/or CD14+ selected monocytes are human newborn MCs or human newborn CD33+ and/or CD14+ selected monocytes. In one embodiment of any of the methods or TCs described, the human MCs or human CD33+ and/or CD14+ selected monocytes are derived from one donor. In one embodiment, the human MCs or human CD33+ or CD14+ selected monocytes are not pooled from more than one donor. In one embodiment of any of the methods or TCs described, the human MCs or human CD33+ and/or CD14+ selected monocytes are obtained from human umbilical cord blood, placenta, bone marrow or circulating peripheral blood. In one embodiment of any of the methods or TCs described, the human MCs are human CD33+ and/or CD14+ selected monocytes. In one embodiment of any of the methods or TCs described, the human MCs or human CD33+ and/or CD14+ selected monocytes are cultured in the presence of human serum albumin. In one embodiment of any of the methods or TCs described, the human MCs or human CD33+ and/or CD14+ selected monocytes are not cultured in the presence of exogenous cytokines or immune response stimulating agent. Non-limiting examples of exogenous cytokines include GM-CSF and IL-4. In one embodiment of any of the methods or TCs described, the human MCs or human CD33+ and/or CD14+ selected monocytes are not cultured in the presence of GM-CSF. In another embodiment of any of the methods or TCs described, the human MCs or human CD33+ and/or CD14+ selected monocytes are not cultured in the presence of exogenously added IL-4. In another embodiment of any of the methods or TCs described, the human MCs or human CD33+ and/or CD14+ selected monocytes are not cultured in the presence of exogenously added GM-CSF and IL-4. In one embodiment of any of the methods or TCs described, the human CD33+ and/or CD14+ monocytes or human MCs and the human platelet poor plasma are autologous, meaning they come from one donor, i.e., the same donor. In one embodiment of any of the methods or TCs described, the period of time sufficient to allow the human MCs or human CD33+ and/or CD14+ monocytes cells to autonomous extravasation of the monolayer of endothelial cells and colonize the cushion of extracellular matrix is at least 0.5 h. In one embodiment of any of the methods or TCs described, the period of time sufficient to allow the human MCs or human CD33+ and/or CD14+ monocytes to autonomous extravasation of the monolayer of endothelial cells and colonize the cushion of extracellular matrix is about 0.5 h to about 4 h. In one embodiment of any of the methods or TCs described, the period of time sufficient to allow the human MCs or human CD33+ and/or CD14+ monocytes to autonomous extravasation of the monolayer of endothelial cells and colonize the cushion of extracellular matrix is about 1.5 h to about 2 h. In one embodiment of any of the methods or TCs described, the adjuvant/antigen/immune response stimulating agent is any agent that can induce or stimulate development, transformation and/or differentiation of the human dendritic cells to become antigen-presenting dendritic cells, the human dendritic cells being derived from human MCs or human CD33+ and/or CD14+ monocytes. In one embodiment of any of the methods or TCs described, the immune response stimulating agent is a vaccine. In one embodiment of any of the methods or TCs described, the antigen or immune response stimulating agent is an adjuvant. In one embodiment of any of the methods or TCs described, the adjuvant, antigen, vaccine or immune response stimulating agent is a pathogen. In one embodiment of any of the methods or TCs described, the pathogen is a fragment/incomplete portion thereof or a whole intact pathogen. In one embodiment of any of the methods or TCs described, the period of time sufficient to allow reverse-transmigrated of the human dendritic cells from the monolayer of endothelial cells is at least 24 h. In one embodiment of any of the methods or TCs described, the period of time sufficient to allow reverse-transmigrated of the human dendritic cells from the monolayer of endothelial cells is about 24 to about 48 h. In one embodiment of any of the methods or TCs described, the period of time sufficient to allow reverse-transmigrated of the human dendritic cells from the monolayer of endothelial cells is about 48 h. In one embodiment of any of the methods or TCs described, the human CD4+ CD45RA+ naïve T cells are CD45RO negative. In one embodiment of any of the methods or TCs described, the human CD4+ CD45RA+ naïve T cells, the dendritic cells and the human platelet poor plasma are autologous, meaning they come from one donor. In one embodiment of any of the methods or TCs described, the human platelet poor plasma is not heat inactivated. In one embodiment of any of the methods or TCs described, the period of time sufficient to cause activation of the naïve T cells in culture is at least one day. In one embodiment of any of the methods or TCs described, the period of time sufficient to cause activation of the naïve T cells in culture is at least 7 days, about 7 days, or about 7 to about 21 days. In one embodiment of any of the methods or TCs described, the adjuvant/antigen/vaccine/immune response stimulating agent being evaluated is the same adjuvant/antigen/vaccine/immune response stimulating agent used in vitro to produce the first and second population of dendritic cells used in evaluating the adjuvant/antigen/vaccine/immune response stimulating agent In one embodiment of any of the methods or TCs described, the methods of in vitro evaluation of vaccine efficacy further comprising analyzing the activated T cells for cell proliferation wherein an increase in cell proliferation or cell number over that in the absence of added dendritic cells indicates that the adjuvant/antigen/vaccine/immune response stimulating agent being evaluated is effective in stimulating human naïve newborn antigen-specific immune response. In one embodiment of any of the methods or TCs described, the methods of in vitro evaluation of vaccine efficacy further comprising challenging the cells in culture of activated T cells with a third population of dendritic cells prior to analysis for cytokines and cell proliferation, wherein the third population of dendritic cells were exposed to the same adjuvant/antigen/vaccine/immune response stimulating agent used in producing the first and second population of dendritic cells used in the method. In one embodiment of any of the methods or TCs described, the third population of antigen-vaccinated human newborn dendritic cells is also produced with the same antigen that is being evaluated. In one embodiment of any of the methods or TCs described, non-limiting the cytokine to be analyzed is selected from a group consisting of IL-1β, IL-2, IL-4, IL-10, IL-12, IFN-gamma and TNF-alpha. Cytokine concentrations induced in the tissue constructs by novel vaccine formulations can be compared to those induced by licensed vaccines in order to benchmark and assess the likelihood that a novel formulation may be too reactogenic and potentially toxic (e.g., if the novel formulation induces much higher levels of pro-inflammatory cytokines). Part DETAILED DESCRIPTION OF THE INVENTION: Unless otherwise explained, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs. Definitions of common terms in molecular biology may be found in Benjamin Lewin, Genes IX, published by Jones & Bartlett Publishing, 2007 (ISBN-13: 9780763740634); Kendrew et al. (eds.), The Encyclopedia of Molecular Biology, published by Blackwell Science Ltd., 1994 (ISBN 0-632-02182-9); and Robert A. Meyers (ed.), Molecular Biology and Biotechnology: a Comprehensive Desk Reference, published by VCH Publishers, Inc., 1995 (ISBN 1-56081-569-8). Further, unless otherwise required by context, singular terms shall include pluralities and plural terms shall include the singular. Unless otherwise stated, the present invention was performed using standard procedures known to one skilled in the art, for example, in Current Protocols in Immunology (CPI) (John E. Coligan, et. al., ed. John Wiley and Sons, Inc.), Current Protocols in Cell Biology (CPCB) (Juan S. Bonifacino et. al. ed., John Wiley and Sons, Inc.), Culture of Animal Cells: A Manual of Basic Technique by R. Ian Freshney, Publisher: Wiley-Liss; 5th edition (2005), Animal Cell Culture Methods (Methods in Cell Biology, Vol. 57, Jennie P. Mather and David Barnes editors, Academic Press, 1st edition, 1998), which are all herein incorporated by reference in their entireties. It should be understood that this invention is not limited to the particular methodology, protocols, and reagents, etc., described herein and as such may vary. The terminology used herein is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the present invention, which is defined solely by the claims. Other than in the operating examples, or where otherwise indicated, all numbers expressing quantities of ingredients or reaction conditions used herein should be understood as modified in all instances by the term “about.” The term “about” when used in connection with percentages will mean±1%. All patents and publications identified are expressly incorporated herein by reference for the purpose of describing and disclosing, for example, the methodologies described in such publications that might be used in connection with the present invention. These publications are provided solely for their disclosure prior to the filing date of the present application. Nothing in this regard should be construed as an admission that the inventors are not entitled to antedate such disclosure by virtue of prior invention or for any other reason. All statements as to the date or representation as to the contents of these documents is based on the information available to the applicants and does not constitute any admission as to the correctness of the dates or contents of these documents. As used herein, the term “comprising” or “comprises” is used in reference to tissue constructs and methods, and respective component(s) thereof, that are essential to the embodiments of the tissue constructs and methods, yet open to the inclusion of unspecified elements, whether essential or not. The use of “comprising” indicates inclusion rather than limitation. Embodiments disclosed herein relate to tissue constructs, methods of making and using such tissue constructs (TCs), and kits for vaccine evaluation for human adult, human newborn, human infants, human adolescents or human children. The kits can also be for evaluation of an adjuvant, an antigen, a vaccine formulation, or an immune-response stimulating agent for human adult, human newborn, human infants, human adolescents or human children. Embodiments disclosed herein are based on the observation that currently known TCs and methods of vaccine evaluation specifically target an adult immune system and do not specifically address the newborns or neonatal immune system which is very different from the adult immune system. Moreover, the current TCs and related methods that employ non-human xenologous materials and non-intact non-autologous, often xenologous, plasma/serum (e.g., fetal bovine serum) do not recapitulate the in vivo immune environment of a human, adult or newborn because the fluid phase factors play an important role in immune responses. As used herein, the term “newborn” refers to a human infant recently or just and lasting through the 28th day following birth or the first four weeks after birth. The terms “newborn” and “neonatal” are used interchangeably. Newborns and young infants have an increased risk of microbial infection. The World Health Organization estimates that over 2,000,000 newborns and infants under 6 months of age die every year due to infection. There is therefore an unmet medical need to prevent these diseases through early in life vaccination. Neonatal antigen (Ag)-presenting cells (APCs) have a reduced ability to mount Th1-polarizing responses. Newborns also show impairment in Ag-specific memory responses and have distinct immune-modulating components in plasma, including low complement levels, increased inhibitory adenosine, and maternal antibodies (Abs). These distinctive features may contribute to the distinct immune responses of newborns and infants and to their susceptibility to infection. Newborns and infants suffer frequent infection and demonstrate impaired responses to many vaccines thereby frustrating efforts to protect this vulnerable population. The susceptibility of newborns to infection and their impaired vaccine responses have been ascribed to distinct immunity of the newborn. For example, the neonatal humoral immunomodulatory components are different from those of an adult. Newborns have lower complement levels, lower plasma concentrations of antimicrobial proteins and peptides, high concentration of immune-modulatory adenosine (selectively inhibits production of Th1-polarizing cytokines), have placenta-derived mediators such as Transforming Growth Factor-β, progesterone, and prostaglandin E2 and have interfering transplacental maternal antibodies. In addition, neonatal leukocyte impairments include high abundance of functionally immature and tolerogenic recent thymic emigrants (naïve T cells), dominance of transitional B cells (impaired T-independent B cell antibody responses), diminished TLR-mediated Th1 polarizing responses (lower Th1:Th2 ratio), lower tumor necrosis Factor (TNF), interferon-α (IFN-α), and IFN-γ, reduced single-cell polyfunctional responses, weaker CD4 lymphoproliferation, lower T cell help to B cells, higher TLR-mediated IL-6 by monocytes and monocyte-derived DCs, and increased number and activity of inhibitory regulatory T cells (Treg cells). Therefore, in this context, characterizing distinct aspects of newborn immunity is important for translational development of new pediatric adjuvants, immunomodulatory agents, vaccine formulations and therapeutics designed for the newborn. A key challenge in studying human immunity is modeling in vitro immune reactions in a physiologically-relevant manner for pre-clinical assessment of safety and efficacy of immunomodualtors, adjuvants and vaccine formulations. Key to responses to vaccines are antigen-presenting cells (APCs), leukocytes that process vaccinal antigens, present them to lymphocytes in the context of MHC-II, produce co-stimulatory signals and thereby trigger adaptive immune responses. Among the most potent and active APCs are dendritic cells (DCs). Activation of circulating blood monocytes (Mos) can induce their differentiation into Mo-derived dendritic cells (MoDCs). Most published studies of neonatal APCs have focused on MoDCs derived by culture of Mos onto plastic culture plates and treatment with high concentrations of exogenous cytokines such as IL-4 and GM-CSF. Although these exogenous cytokine-driven DCs are useful model system, their relationship to DCs that exist in vivo does not fully recapitulate the true in vivo immune environment in a subject. Indeed, multiple variables affect immune responses, including age of the study subject, the composition of culture media and inclusion of plasma, as well as interactions of leukocytes with endothelial cells and with the extracellular matrix. Immunization of newborns and young infants provides important benefits to reduce the burden of early life infection. Birth is the most reliable point of healthcare contact worldwide, and thus neonatal immunization would provide higher vaccination coverage and will narrow the window of susceptibility inherent to many 2/4/6 month immunization schedules. While pediatric vaccines represent the majority of the vaccine market, getting a new vaccine out represents a huge investment. It is known that from discovery and preclinical assessment going all the way down to clinical trials, registration and production, a drug candidate can cost a billion dollars and more than 10 years of work. One important reason for this excessive cost and time is the high failure rate observed at late stages in development. It is generally accepted that animal testing are helpful but not 100% reliable in predicting human immune responses. One could argue then that more reliable preclinical assessment of vaccines candidates could help increase success rate. From here, the idea of using primary human cultures that faithfully recapitulate the immune responsiveness to vaccines as observed in vivo becomes highly appealing; and this is particularly true for newborn vaccines where animal models and adult human cells for preclinical assessment are not predictive of human neonatal and infant responses. A related key need is to improve preclinical assessment of the safety of candidate immunomodulators, adjuvants or vaccine formulations to exclude those that may be too reactogenic/toxic. Examples of reactogenicity in vivo include local swelling and pain, fevers, febrile seizures, and other more serious adverse events (see Ahmed, S S et al., Sci. Trans. Med. 2011). Vaccination at birth has been successfully proven in veterinary medicine with oral in utero immunization of sheep and poultry industry routinely vaccinating in ovo. Neonatal vaccination can also be safe and effective in human newborns with vaccines such as BCG (Mycobacterium bovis) for tuberculosis and HBV for hepatitis B. However, the number of vaccines that have proven safe and effective at birth are very limited due in part to incomplete characterization of neonatal immune responses. Studies of adults are not predictive of neonatal responses as growing evidence indicates that newborns manifest a distinct skew to their innate and adaptive immune responses (PrabhuDas M, et al., Nat, Immunol. 2011 March; 12(3):189-94). Adjuvants are vaccine components that enhance immunogenicity of vaccinal antigens in vivo. Although there has been a great increase in information regarding candidate adjuvants, few are currently approved for use in human vaccines. Alum, MF59 and naturally occurring endotoxins derived from antigens' manufacturer are the most common Besides, this limitation, there is the need to explore new adjuvants that could be effective and safe for newborn babies. Given the unmet need for safe and effective vaccines to be given in early life, an in vitro test system that uses primary cells of human newborn origin was developed. Such a system provides more accurate data of expected newborn immune reactogenicity to vaccines. Moreover, developing a wholly human in vitro test system that do not use non-human xenologous materials would also provide more accurate data of expected immune reactogenicity to vaccines when testing human newborns and human non-newborns, e.g., adults, adolescents and children. It is encompassed herein that the age of the individuals from which cells (i.e., newborns) were obtained and the complexity inherent to the fluid/plasma phase of the age-matched individual would be taken into account in the various embodiments of the in vitro test systems disclosed. In 1998, Gwendalyn J. Randolph published an article demonstrating how autonomous extravasated monocytes in vitro were autonomously differentiating into strong APCs after 48 hours of stimulation (Science October 16; 282 (5388): 480-3). She used human primary endothelial cells, and adult peripheral blood mononuclear cells (PBMCs) in a tissue construct setting. However, she employed M199 media with 20% heat-inactivated heterologous human serum that does not reflect the immune-modulating bioactivities of untouched autologous human plasma. Similar systems using only adult cells are described in U.S. Patent Publication No. US20100287630 and US20050282148. Of note, all these systems have used heat-treated fetal calf serum or heat-treated human plasma that do not reflect the bioactivity of unmodified autologous heparinized, cryopreserved plasma that were used in the tissue construct (TC) work comprised in the in vitro test system described herein. Cation chelants are the standard anticoagulant used in general. The non-removal of these cations plays a role in much better (in vivo-like) bioactivity. Moreover, none of the published studies or patents teaches the use of neonatal, cord or placenta blood cells, non-heated plasma or take into consideration the plasma adensoine system known to exert profound effects on the responsiveness of primary leukocytes, especially neonatal cells. (Levy 0. J. Immunol 2006; Coombs, M R P et al., Expert Reviews in Anti-Infective Therapy 2011). Furthermore, none of the published studies or patents teaches the use of only human derived materials for making the TCs that evaluate the immune
{'bibliographic_information': "{'country': 'US', 'doc-number': '14383358', 'kind': 'B2', 'date': '20130307', 'extension': '830', 'invention_title': 'Methods of evaluating immunogenicity of an agent using an artificial tissue construct'}", 'source_file': './grant/2020/ipg200804.xml', 'source_data': 'USPTO-Grant'}